OncoDxRx

OncoDxRx's Spectacular PGA Technology Besides providing dazzling gene-to-drug technology—the latest liquid biopsy craze—is digging into rich cell-free mRNA data sets and uncovering meaningful results Gene-to-drug is poised to become the “next big thing” in precision medicine. On the strength of new PGA technologies, it promises to elevate an ambitious concept—the matching and prediction of the best drug(s) at the patient’s and molecular levels. Although the concept has been around for decades, transformational technologies are taking it to new heights. Indeed, PGA technology promises to usher gene-to-drug into a bright new era. We use lots of fancy terms, but gene-to-drug still means predicting drug response from gene patterns or signatures. Why is PGA so powerful? According to OncoDxRx, it provides the ability to understand the relationship between gene signature and mechanism of action of drug. PGA is expected to be especially valuable as a means of broadening the coverage of tailored personalized diagnostics and therapeutics for those cancer patients currently excluded from precision medicine, i.e., no actionable mutation detected following current NCCN testing workup. A tumor is not a tumor is not a tumor. Each tumor has a profile that depends on the tumor’s location and what the tumor microenvironment is. The PGA technology enabled an analysis of the gene expression fingerprints that predict to be responsive to certain drug(s). More specifically, the technology allowed hundreds of existing anticancer drugs to be examined in a single analysis. OncoDxRx’s team was able to take patient’s blood, profile gene expression, and report out a list of most effective, effective and less effective drugs within 5 days. Moreover, the team can deconvolute which class of drugs were most likely to have an effect. PGA is impressive not just for the depth of its analyses, but for the breadth of its applications. We welcome investment, licensing and partnership! #technology #medicine #data #testing #cancer #oncology #liquidbiopsy #team #precisiononcology

Build cancer theranostic intelligence foundations for each patient Accurate intelligence is the foundation of any successful operation in an ever-changing world. With interconnected data and real-time patient testing, OncoDxRx’s exclusive technologies can explore next-gen cancer-fighting capabilities and equipment and quickly improve clinical outcomes. Patient-critical data on-hand, when you need it Accurate tumor intelligence doesn't just give you an edge; it gives you operational certainty. Ensure a real advantage with OncoDxRx’s one-of-a-kind precision oncology technologies. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing #cancerresearch #personalizedmedicine #targetedtherapy #PrecisionOncology #Therapy 

AI Analyzes cfDNA Ends from Liquid Biopsies to Detect Cancer There may be new hope in the hunt for reliable ways to detect cancer early on, an area where traditional diagnostic methods often prove inadequate. By analyzing cell-free DNA (cfDNA) end-motifs, AI can now distinguish between cancer patients and healthy individuals, according to a research article  published in npj Precision Oncology. A model based on deep learning called end-motif inspection via transformer (EMIT) was created using thousands of samples from various studies that included cfDNA sequencing for hepatocellular carcinoma, colorectal cancer, non-small cell lung cancer, and esophageal carcinoma. Tested on whole exome sequencing data from both lung cancer and non-cancer patients, EMIT demonstrated strong classification capabilities. EMIT is an advance toward a standardized deep-learning method for identifying cfDNA fragmentome end-motifs. EMIT was created using data from 4606 plasma cfDNA samples collected using various sequencing methods. While EMIT was developed using only end-motif frequencies and not cancer state information, cancer-discriminatory features are encoded and represented. When applied to six datasets produced by various sequencing methods, EMIT demonstrated excellent classification performance in cancer detection. Additionally, using a separate cfDNA testing set from whole-exome sequencing, the researchers demonstrated excellent classification performance in identifying lung cancer using linear projections of EMIT representations. One disadvantage of using only end-motifs rankings as input to EMIT is that it disregards other information shown to aid in cancer detection, such as size profile, aberrant coverage, preferred end coordinates, and somatic mutations. Not to mention that tumor-derived cfDNA is scarce, particularly in early-stage cancer patients. Once cancerous material enters the bloodstream and mixes with signals from healthy cells, the cancer signal is greatly diminished. Increasing tumor signals may be possible through the enrichment of tumor-derived cfDNA by excluding background cfDNA based on the distribution of size profiles. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing #cancerresearch #personalizedmedicine #targetedtherapy #PrecisionOncology #Therapy 

Scientists Have Created Transparent Mice, Making Research Even Easier “You could see through the mouse. I’ve been working in optics for 30 years, and I thought that result was jaw-dropping." The method is topical and non-invasive, which could be extremely appealing to people in not only research but in medicine overall. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing #cancerresearch #personalizedmedicine #targetedtherapy #PrecisionOncology #Therapy 

Non-responders of precision medicine: it’s time to better predict patients’ response. Different patients respond to precision medicine in different ways, and the precision treatments are not effective for everyone. Investigators from OncoDxRx use transformative techniques to predict patient response, advancing the promise of precision medicine for non-responders. https://lnkd.in/gvKNT9Gn #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing #cancerresearch #personalizedmedicine #targetedtherapy #PrecisionOncology #Therapy 

Behind The Breakthroughs: Weaving Transcriptomic Profiling Across Cancer Care OncoDxRx proposes that PGA test must integrate into clinical oncology NGS diagnostics to advance the democratization of cancer treatment. For many cancer patients today, the question is becoming less about whether there’s a treatment for their condition and more about which one is the right one. Despite tremendous improvement in cancer treatments, there are significant delays and unavailability in matching patients to targeted therapies. For these medicines to be widely used, tumor profiling with next-generation sequencing (NGS) must pair with PGA (Patient-derived Gene expression-informed Anticancer drug efficacy) test to first become commonplace. OncoDxRx emphasizes the significance of paired genomic (for responders) and transcriptomic (for non-responders) profiling within the cancer care continuum, ensuring the accessibility of personalized oncology treatment for all individuals. We understood how exciting it was to see new precision therapies on the market, but there was a gap between therapy and patient, which were the low patient eligibility and response rates. We have some fantastic drugs, but are we actually using them? Unfortunately, the answer is no. We are unable to link patients to precision medicines. The full power of precision medicine will only be realized once it is available and working in EVERY PATIENT.   #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing #cancerresearch #personalizedmedicine #targetedtherapy #PrecisionOncology #Therapy 

OncoDxRx was formed to adapt to the changes in the precision medicine era and to the threats cancer patients will be faced with in the coming years. Our new operating mode promotes innovation and accessibility, which are vital for defending the interests of all patients. Instead of analyzing specific DNA mutations by looking for one misarranged base out of billions of sequences, OncoDxRx’s investigators devised a new approach to identify distinct gene expression patterns in patients’ own cell-free mRNA. This liquid biopsy transcriptomics approach requires about five times less blood and cost than required by NGS based DNA biomarker testing, and with 5-day turnaround. Currently, there's typically a wait of weeks to months before we can fully execute the treatment plan. #opportunities #strategy #programmin, g #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing #cancerresearch #personalizedmedicine #targetedtherapy #PrecisionOncology #Therapy 

Newly Developed Small Molecule Found Effective against 13 of 17 KRAS Mutant Cancers Researchers have developed a promising new small-molecule drug that has shown efficacy against 13 of the 17 most common KRAS mutant-driven cancers. Details of this new research are published in the journal Science. KRAS mutations are implicated in between 17 percent and 25 percent of all cancers, but current therapies are limited, primarily targeting only G12C mutations, which leaves as many as 50 percent of patients with cancer driven by a KRAS mutation without targeted treatment options. But the newly developed molecule ACBI3 shows promise to address a much broader range of KRAS mutation-driven cancers and takes a different approach than the traditional attempts of KRAS targeted drug development. Instead of attempting to inhibit the activity of mutant KRAS, ACBI3 degrades the mutant genes. It was based on a class of small molecules called PRoteolysis TArgeting Chimeras (PROTACs). Unlike traditional inhibitors that target a single mutation, ACBI3 has shown it can rapidly eliminate 13 out of the 17 most common KRAS mutants with high potency and selectivity. In preclinical mouse models, it induced effective tumor regression, demonstrating significant potential for KRAS degradation as a transformative therapeutic method. The mechanism behind ACBI3’s efficacy involves the use of PROTACs, which consist of two “prongs.” One prong attaches to the target protein—KRAS in this case—while the other prong recruits an E3 ligase, a component of the cell’s natural disposal system called the ubiquitin-protease. This tags the target protein as “expired” which alerts the ubiquitin protease to rapidly degrade that protein. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing #cancerresearch #personalizedmedicine #targetedtherapy #PrecisionOncology #Therapy 

OncoDxRx’s PGA and its loyal wingman OncoMRD technologies anticipate the evolution of future precision oncology While OncoDxRx’s liquid biopsy functional genomics pipelines are beginning to bear fruits, these transformative and exclusive technologies outline new perspectives, both operational and commercial, for this couple. PGA–OncoMRD, which is much more akin to a move towards the new generation of precision oncology than to an iterative evolution of liquid biopsy. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing #cancerresearch #personalizedmedicine #targetedtherapy #PrecisionOncology #Therapy 

Mapping Cancer Drug Resistance Mutations and Mechanisms A new study headed has indicated how mutations that cause cancer drug resistance fall into one of four categories. The work detailed each of the four types of mutation, outlining how known mutations impact drug resistance, and also highlighting new DNA mutations that could be explored further. The results also indicate possible second-line cancer treatment options based on an individual’s genetic makeup. The team’s paper was published in Nature Genetics, titled “Base editing screens define the genetic landscape of cancer drug resistance mechanisms,” in which they concluded, “Our variant-to-function map has implications for patient stratification, therapy combinations and drug scheduling in cancer treatment.” However, current methods for identifying drug-resistance mutations require multiple samples from patients collected over a long time, making this a time-consuming and difficult process. This is “a slow process. For their newly reported work to gather large-scale information on cancer mutations the researchers used CRISPR gene editing and single-cell genomic techniques to investigate the impact of multiple drugs across human cancer cell lines and organoid cell models. By combining these techniques, they were able to create a map showing drug resistance across colon cancer, lung cancer, and Ewing sarcoma cell lines. These were chosen as they are prone to developing resistance and have limited second-line treatments available. The team found that cancer mutations fall into four different categories dependent on the impact of the DNA change. Of these four types, drug resistance mutations, otherwise known as canonical drug resistance mutations, are genetic changes in the cancer cell that lead to the drug being less effective. Drug addiction mutations lead to some of the cancer cells using the drug to help them grow, instead of destroying them. Driver mutations are gain-of-function genetic changes that allow cancer cells to use a different signaling pathway to grow, avoiding the pathway that the drug may have blocked. The fourth category, sensitizing variants, comprises genetic mutations that make the cancer more sensitive to certain treatments, and could mean that patients with these genetic changes in their tumor would benefit from particular drugs. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing #cancerresearch #personalizedmedicine #targetedtherapy #PrecisionOncology #Therapy